|
Market Closed -
TEL AVIV STOCK EXCHANGE
06:44:01 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 2,397.00 ILa | -0.83% |
|
-1.88% | +6.06% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
Business description: Kamada Ltd.
Number of employees: 462
Sales by Activity: Kamada Ltd.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Proprietary Products | 75.52M | 103M | 115M | 141M | 156M |
Distribution | 28.12M | 26.74M | 27.06M | 19.51M | 24.25M |
Geographical breakdown of sales: Kamada Ltd.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
U.S.A | - | - | 73.74M | 101M | 99.64M |
Israel | 35.77M | 32.03M | 31.3M | 25.01M | 29.56M |
Latin America | 9.13M | 11.29M | 12.93M | 18.61M | 24.22M |
Canada | - | - | 11.16M | 9.46M | 10.8M |
Europe | 5.68M | 5.28M | 7.09M | 4.94M | 9.45M |
Asia | 3.17M | 4.58M | 6.15M | 2.38M | 6.72M |
Others | 134K | 305K | 157K | 62K | 56K |
U.S.A and North America | 49.76M | 75.85M | - | - | - |
Executive Committee: Kamada Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 58 | 2015-06-30 |
Chaime Orlev
DFI | Director of Finance/CFO | 56 | 2017-12-30 |
Eran Nir
COO | Chief Operating Officer | 54 | 2016-10-31 |
Nir Livneh
LAW | General Counsel | 48 | 2009-12-31 |
Liron Reshef
HRO | Human Resources Officer | 56 | 2022-12-31 |
Composition of the Board of Directors: Kamada Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
David Tsur
BRD | Director/Board Member | 75 | 1990-12-12 |
Leon Recanati
CHM | Chairman | 77 | 2013-03-06 |
| Chairman | 55 | 2020-08-11 | |
Ishay Davidi
BRD | Director/Board Member | 64 | 2019-12-23 |
| Director/Board Member | 49 | 2019-12-23 | |
Lilach Payorski
BRD | Director/Board Member | 53 | 2021-12-15 |
Uri Botzer
BRD | Director/Board Member | 38 | 2022-11-30 |
Benjamin Dekel
BRD | Director/Board Member | 60 | 2023-08-28 |
Assaf Itshayek
BRD | Director/Board Member | 53 | 2023-08-28 |
Company details: Kamada Ltd.
Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.83% | -1.88% | +7.20% | +38.32% | 445M | |
| -2.54% | +1.31% | +54.27% | +114.96% | 1,135B | |
| -1.42% | +3.23% | +38.56% | +74.44% | 635B | |
| +0.16% | +0.08% | +25.29% | +95.23% | 505B | |
| -0.31% | +3.09% | +44.14% | +64.80% | 378B | |
| -1.34% | -0.47% | +66.04% | +41.00% | 358B | |
| -0.68% | +2.65% | +22.98% | +50.39% | 295B | |
| -1.20% | +3.04% | +2.33% | +22.86% | 266B | |
| -1.79% | +1.57% | +50.56% | +59.08% | 237B | |
| -0.73% | -0.10% | +29.02% | +99.67% | 193B | |
| Average | -1.07% | +1.76% | +34.04% | +66.07% | 400.41B | |
| Weighted average by Cap. | -1.35% | +2.66% | +41.02% | +79.75% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KMDA Stock
- Company Kamada Ltd.
Select your edition
All financial news and data tailored to specific country editions
